What diseases are mivamutin injection mainly used to treat?

Mifamurtide injection (Mifamurtide) is an immune enhancer mainly used to treat osteosarcoma, especially patients with high-grade, resectable, non-metastatic osteosarcoma. Osteosarcoma is a rare and aggressive cancer that usually affects children, teenagers and young adults, and is particularly common in people under the age of 30. Osteosarcoma generally originates in the skeletal system, particularly the long bones of the extremities, especially the femur, tibia, and humerus. Because it occurs at a special site and usually invades surrounding soft tissues, it is difficult to treat and has a poor prognosis.

Mivamutide is an immunomodulatory drug that is often used as adjuvant therapy after surgical resection. It reduces the risk of osteosarcoma recurrence by activating the body's immune system to help identify and destroy any remaining cancer cells. The mechanism of action of mivamutin involves enhancing the recognition and attack of tumor cells by macrophages, prompting the body's immune system to produce an anti-tumor immune response. Clinical studies have shown that mivamutide can improve patients' disease-free survival (DFS) and help improve overall survival rate.

For most patients with osteosarcoma, surgical removal of the tumor is the most common treatment. However, surgical treatment often cannot completely eliminate all cancer cells in the body, especially those tiny residual tumor cells that cannot be detected by imaging tests. By activating the immune system, mivamut helps reduce the likelihood of these tiny tumor cells reappearing in the body.

The clinical application of mivamutide is mainly targeted at children, adolescents and young adults, especially those with high-grade, resectable, non-metastatic osteosarcoma after complete gross surgical resection. In these patients, mivamutide is used as an adjuvant treatment after surgery to help improve the patient's long-term survival rate and reduce disease recurrence. Usually, mivamutide is not used as a separate treatment for osteosarcoma, but is used in combination with other treatments such as surgery and chemotherapy as part of a comprehensive treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact